15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

Intra-Abdominal Sepsis & Source Control

Intra-abdominal infections (IAIs) encompass a wide spectrum of pathological processes ranging from localized visceral inflammation to life-threatening generalized peritonitis and septic shock. Surviving sepsis in intra-abdominal pathology hinges on rapid diagnostic categorization, immediate resuscitation, targeted broad-spectrum antimicrobial coverage, and prompt surgical or percutaneous source control.

Classification of Peritonitis

1. Primary Peritonitis (Spontaneous Bacterial Peritonitis [SBP]):
   • Pathogenesis: Monomicrobial infection of ascitic fluid occurring without an anatomical macroscopic breach of the gastrointestinal tract, predominantly arising in patients with end-stage liver disease and portal hypertension. Bacterial translocation from the gut lumen into mesenteric lymphatics leads to bacteremia and hematogenous seeding of ascitic fluid.
   • Microbiology: Enteric Gram-negative bacilli (Escherichia coli, Klebsiella pneumoniae) and Streptococcus species.
   • Diagnosis & Therapy: Diagnostic paracentesis demonstrating an ascitic fluid absolute polymorphonuclear (PMN) count $\ge 250/\mu\text{L}$ (calculated as $\text{Total Nucleated Cells} \times \%\text{Neutrophils}$). First-line treatment is a third-generation cephalosporin (Ceftriaxone $2\text{ g}$ IV q24h) plus intravenous albumin ($1.5\text{ g/kg}$ within 6 hours of diagnosis, followed by $1.0\text{ g/kg}$ on Day 3) to prevent hepatorenal syndrome and reduce mortality.
2. Secondary Peritonitis:
   • Pathogenesis: Direct loss of gastrointestinal tract mucosal integrity leading to contamination of the sterile peritoneal cavity (perforated appendicitis, perforated diverticulitis, peptic ulcer perforation, bowel ischemia/infarction, or postoperative anastomotic dehiscence).
   • Microbiology: Dynamic polymicrobial synergy. Aerobic and facultative Gram-negative bacilli (E. coli, Klebsiella, Proteus) and Enterococci trigger early acute endotoxemia and systemic sepsis, whereas obligate anaerobes (Bacteroides fragilis, Peptostreptococcus, Clostridium species) drive secondary fibrin deposition and intra-abdominal abscess formation.
3. Tertiary Peritonitis:
   • Pathogenesis: Persistent or recurrent intra-abdominal infection occurring $> 48\text{ hours}$ after apparently successful surgical source control of secondary peritonitis. Characterized by ongoing systemic inflammation, multiorgan dysfunction, and failure to clear peritoneal contamination.
   • Microbiology: Colonization by low-virulence, opportunistic, and multidrug-resistant nosocomial pathogens: Enterococcus faecium, Candida species (C. albicans, C. glabrata), Pseudomonas aeruginosa, Acinetobacter baumannii, and coagulase-negative staphylococci. Treatment requires aggressive intensive care support and tailored antimicrobial regimens covering resistant Gram-negatives, resistant enterococci, and fungi.

The Primacy of Source Control

Source control represents the physical control of the infectious focus and the mitigation of ongoing microbial contamination. Common source control interventions include:

• Resection or primary repair of perforated visceral organs (e.g., sigmoid colectomy with Hartmann pouch for perforated diverticulitis).
• Drainage of localized fluid collections and purulent abscesses (percutaneous CT- or ultrasound-guided catheter drainage is preferred over open surgical drainage for discrete, well-defined collections).
• Debridement of non-viable tissue (e.g., necrotizing pancreatitis step-up approach: initial conservative medical stabilization $\rightarrow$ percutaneous catheter drainage $\rightarrow$ minimally invasive video-assisted retroperitoneal debridement [VARD] or endoscopic transgastric necrosectomy).

Antimicrobial Duration: The STOP-IT Trial

Historically, clinicians continued antibiotic therapy in intra-abdominal infections until complete normalization of fever, leukocytosis, and bowel function, frequently resulting in 10- to 14-day courses. The landmark STOP-IT Trial (Study to Optimize Peritoneal Infection Therapy; Sawyer et al., NEJM 2015) randomized 518 patients with complicated intra-abdominal infections and adequate surgical or percutaneous source control to either:

• Experimental Group: A short, fixed course of antimicrobial therapy for $4.0 \pm 1.0\text{ days}$ (approximately 96 hours) regardless of fever or leukocytosis.
• Control Group: Traditional therapy continued until 2 days after the resolution of fever, leukocytosis, and ileus, up to a maximum of 10 days (median actual duration 8 days, versus 4 days in the short-course group).

Trial Outcomes: The incidence of composite adverse outcomes (surgical site infection, recurrent intra-abdominal infection, or death) was identical between both arms ($21.8\%$ in the experimental short-course group vs. $22.3\%$ in the traditional group).

Clinical Takeaway: In patients who achieve definitive source control, a 4-day course of post-procedure antimicrobial therapy is fully sufficient. If a patient exhibits persistent fever, leukocytosis, or clinical deterioration after 4 to 7 days, the proper management is urgent repeat diagnostic imaging (contrast-enhanced CT of the abdomen and pelvis) to identify recurrent collections or failure of source control, not the reflexive, empirical escalation of broad-spectrum antibiotics.

Acute Cholangitis: Pathophysiology and Emergency Biliary Decompression

Acute cholangitis occurs when biliary outflow obstruction (choledocholithiasis, benign stricture, or malignant obstruction) increases intrabiliary intraductal pressure ($> 20\text{--}25\text{ cmH}_2\text{O}$). High pressure breaks down the tight junctions between hepatocytes and biliary canaliculi, facilitating the rapid translocation of bacteria and endotoxins into the hepatic venous circulation, resulting in severe bacteremia and septic shock.

• Clinical Presentation:
  • Charcot Triad: Fever, right upper quadrant abdominal pain, and jaundice (present in $50\text{--}70\%$ of cases).
  • Reynolds Pentad: Charcot triad plus hypotension (shock) and altered mental status/confusion (indicates acute obstructive suppurative cholangitis, a catastrophic ICU emergency).
• Emergency Management:
  • Resuscitation: Fluid resuscitation and immediate broad-spectrum IV antibiotics covering enteric Gram-negatives and anaerobes (e.g., Piperacillin-tazobactam or Cefepime plus Metronidazole).
  • Urgent Biliary Decompression within 24 Hours: Endoscopic Retrograde Cholangiopancreatography (ERCP) with biliary sphincterotomy and stent placement is the gold standard decompression technique. In patients presenting with septic shock or Reynolds pentad, decompression must be performed emergently ($< 12\text{--}24\text{ hours}$). If ERCP is unavailable or anatomically impossible (e.g., prior Roux-en-Y gastric bypass), percutaneous transhepatic cholangiography (PTC) or surgical decompression is mandatory.

---

Necrotizing Soft Tissue Infections (NSTI)

Necrotizing soft tissue infections (NSTIs) are aggressive, life-threatening infections characterized by extensive necrosis of the skin, subcutaneous tissue, superficial fascia, and deep muscular fascia. Mortality ranges from $20\%$ to over $40\%$ and correlates directly with time to initial surgical debridement.

Microbiological Classification

• Type 1 (Polymicrobial, $\sim 70\text{--}80\%$):
  • Synergistic mixture of obligate anaerobes (Bacteroides, Peptostreptococcus, Clostridium) and aerobic Gram-negative and Gram-positive bacilli (E. coli, Klebsiella, Enterobacter, Staphylococcus).
  • Typically develops in elderly patients, individuals with poorly controlled diabetes mellitus, peripheral vascular disease, immunosuppression, or post-surgical wounds.
  • Fournier Gangrene: A specific Type 1 NSTI of the perineum, perianal region, and external genitalia, typically originating from a perianal abscess, urethral stricture extravasation, or colorectal perforation.
• Type 2 (Monomicrobial, $\sim 20\%$):
  • Classically caused by Group A Streptococcus (Streptococcus pyogenes / GAS), alone or co-infecting with Staphylococcus aureus (particularly community-acquired MRSA carrying the Panton-Valentine leukocidin [PVL] gene).
  • Frequently affects younger, previously healthy, immunocompetent hosts following minor cuts, blunt contusions, insect bites, or non-penetrating muscle strain.
  • Highly associated with Streptococcal Toxic Shock Syndrome (STSS).
• Special Pathogens:
  • Vibrio vulnificus: Halophilic marine organism causing fulminant NSTI following saltwater exposure or raw oyster ingestion; classically severe in patients with liver cirrhosis and hemochromatosis.
  • Clostridium perfringens: Gas gangrene (clostridial myonecrosis) following major traumatic wounds, soil contamination, or crush injuries.

Clinical Presentation and Diagnostic Pitfalls

• Cardinal Early Sign: Severe pain out of proportion to superficial physical exam findings. The patient experiences agonizing local tenderness that extends well beyond the visible borders of skin erythema.
• Evolution of Physical Signs: Mild localized erythema and non-pitting, "wooden"-hard edema $\rightarrow$ duskiness, bronze or purplish discoloration $\rightarrow$ bullae (initially serous, progressing to hemorrhagic) $\rightarrow$ cutaneous anesthesia (due to thrombosis of nutrient subcutaneous microvessels and infarction of superficial cutaneous nerves) $\rightarrow$ skin breakdown, frank gangrene, and crepitus.
• Crepitus: Indicates soft tissue gas production. Present in $30\text{--}50\%$ of Type 1 polymicrobial and clostridial infections, but absent in pure Type 2 Group A Streptococcal NSTI. The absence of subcutaneous gas or crepitus never excludes necrotizing fasciitis.

The LRINEC Score and Its Limitations

The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score incorporates 6 laboratory parameters: C-reactive protein (CRP $\ge 150\text{ mg/L}$), total white blood cell count, hemoglobin, serum sodium ($< 135\text{ mEq/L}$), serum creatinine ($> 1.6\text{ mg/dL}$), and glucose ($> 180\text{ mg/dL}$).

• Score $\ge 6$ raises suspicion; score $\ge 8$ correlates with high probability.

Necrotizing Soft Tissue Infection vs. Cellulitis

Surgical and Medical Management of NSTI

1. Emergent Surgical Debridement: Definitive diagnosis and cure require operative exploration. A bedside "finger test" (a small $2\text{-cm}$ incision under local anesthesia along the deep fascia) confirms the diagnosis if the surgeon encounters no tissue resistance to blunt finger dissection, lack of bleeding along thrombosed fascial planes, and presence of thin, malodorous, grayish exudate ("dishwater pus"). Radical excision of all necrotic, non-bleeding fascia and muscle must be performed immediately, followed by scheduled "second-look" re-explorations every 24 hours until tissue viability is secured.
2. Antimicrobial Regimen:
   • Broad-spectrum Gram-positive and MRSA coverage: Vancomycin ($15\text{--}20\text{ mg/kg}$ IV q8-12h) or Daptomycin ($8\text{--}10\text{ mg/kg}$ IV q24h).
   • PLUS Broad-spectrum Gram-negative and anaerobic coverage: Piperacillin-Tazobactam ($4.5\text{ g}$ IV q6h) OR Meropenem ($1\text{ g}$ IV q8h).
   • PLUS Clindamycin ($600\text{--}900\text{ mg}$ IV every 8 hours).

The Eagle Effect and Clindamycin Mechanism

• The Eagle Effect: Beta-lactam antibiotics (penicillins and cephalosporins) exert their bactericidal effect by binding to penicillin-binding proteins (PBPs) during active bacterial cell wall synthesis. In high-inoculum, deep-tissue infections, bacteria enter the stationary growth phase, markedly downregulating PBP expression. Consequently, penicillin and beta-lactam bactericidal efficacy drops dramatically in advanced necrotizing fasciitis.
• Clindamycin Toxin Suppression: Clindamycin functions as a protein synthesis inhibitor by reversibly binding to the 50S ribosomal subunit. Its efficacy is entirely independent of bacterial growth phase or inoculum size. Clindamycin rapidly shuts down the transcription and ribosomal synthesis of streptococcal pyrogenic exotoxins (SpeA, SpeB, SpeC), streptolysin O, and clostridial alpha-toxin, arresting cytokine storm, vasoplegic shock, and capillary leak syndrome.
• Intravenous Immunoglobulin (IVIG): Dosed at $1\text{ g/kg}$ on Day 1, followed by $0.5\text{ g/kg}$ on Days 2 and 3. Indicated as an adjunctive therapy in severe Streptococcal Toxic Shock Syndrome (STSS) associated with NSTI to neutralize circulating streptococcal superantigens.

---

Central Nervous System Infections: Acute Bacterial Meningitis

Acute bacterial meningitis is a life-threatening neuro-infectious emergency requiring immediate diagnostic risk stratification and urgent empiric therapy. Cortical inflammation, cerebral edema, elevated intracranial pressure (ICP), and ischemic strokes account for high acute mortality ($15\text{--}25\%$) and persistent neurological morbidity (sensorineural hearing loss, seizures, cognitive deficits).

Pathogen Spectrum by Host Demographics

• Streptococcus pneumoniae: The most common overall pathogen across all adult age groups, accounting for $> 50\%$ of adult bacterial meningitis cases. Associated with contiguous spread (otitis media, mastoiditis, sinusitis), basilar skull fractures with CSF leak, asplenia, and highest mortality.
• Neisseria meningitidis: Young adults, military personnel, and college students. Rapid progression with distinctive petechial and purpuric cutaneous lesions (purpura fulminans). May precipitate bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome).
• Listeria monocytogenes: Adults aged $> 50\text{ years}$, pregnant women, alcoholics, solid organ transplant recipients, and individuals with hematologic malignancies or receiving immunosuppressive therapy (corticosteroids, TNF inhibitors). Listeria is intrinsically resistant to all cephalosporins due to low binding affinity to its penicillin-binding proteins.

Diagnostic Approach & Indications for Pre-LP Neuroimaging

Definitive diagnosis requires a lumbar puncture (LP) to assess opening pressure, cerebrospinal fluid (CSF) cell count with differential, CSF glucose, protein, Gram stain, and multiplex PCR. However, performing an LP in a patient with a cerebral mass lesion or significant brain shift carries a theoretical risk of precipitating fatal uncal or transtentorial brain herniation.

Specific Indications for Head CT PRIOR to Lumbar Puncture (IDSA Guidelines):

1. Focal neurological deficits (e.g., hemiparesis, visual field cut, facial asymmetry; excludes isolated cranial nerve VI or VII palsies).
2. New-onset seizure within the preceding 1 week.
3. Abnormal level of consciousness (the 2016 ESCMID guideline uses a GCS score $< 10$ as its threshold).
4. Papilledema on fundoscopic examination (indicates elevated ICP).
5. Immunocompromised host (HIV/AIDS, immunosuppressive medications, post-transplantation).
6. History of central nervous system disease (mass lesion, stroke, or focal infection).

                    SUSPECTED BACTERIAL MENINGITIS
                                │
          ┌─────────────────────┴─────────────────────┐
          ▼                                           ▼
  Pre-LP Head CT Criteria Present?            No CT Criteria Present:
  - Focal neurologic deficit                  - Normal sensorium
  - New seizure within 1 week                 - No focal neurological signs
  - Severely depressed GCS (<10)              - No papilledema
  - Papilledema                               - Immunocompetent
  - Immunocompromised state or prior CNS disease      │
          │                                           ▼
          │ YES                               IMMEDIATE LUMBAR PUNCTURE
          ▼                                   Followed immediately by
  1. DRAW BLOOD CULTURES                      Dexamethasone + Antibiotics
  2. ADMINISTER IMMEDIATELY:
     - IV Dexamethasone (10 mg)
     - Empiric Antibiotics
  3. PERFORM NON-CONTRAST HEAD CT
  4. PERFORM LUMBAR PUNCTURE (if no shift)

Empiric Antimicrobial Regimens & Dexamethasone Protocols

Adjunctive Dexamethasone Protocol

• Dosing and Administration: Dexamethasone $10\text{ mg}$ IV administered 15 to 20 minutes BEFORE, or at the latest CONCURRENTLY WITH, the first dose of antimicrobial therapy, continued at $10\text{ mg}$ IV every 6 hours for 4 days.
• Pathophysiological Rationale: Antibiotic-mediated lysis of bacteria releases large amounts of cell wall components (peptidoglycans, teichoic acid, lipopolysaccharide, and pneumolysin) into the subarachnoid space, triggering an intense burst of meningeal neuroinflammation, cerebral edema, elevated intracranial pressure, and neuronal apoptosis. Administering corticosteroids prior to bacteriolysis downregulates pro-inflammatory cytokine expression (TNF-$\alpha$, IL-1$\beta$).
• Clinical Evidence: The European Dexamethasone Study (de Gans and van de Beek, NEJM 2002) established that early adjunctive dexamethasone reduces 8-week mortality ($7\%$ vs. $15\%$) and unfavorable neurological outcomes—particularly severe sensorineural hearing loss—in adults with Streptococcus pneumoniae meningitis.
• De-escalation Rule: IDSA advises continuing dexamethasone only when Streptococcus pneumoniae is confirmed and stopping it for other causes; the 2016 ESCMID guideline continues it for S. pneumoniae or Haemophilus influenzae and stops it when bacterial meningitis is excluded or another organism (for example Listeria) is identified.